AU568709B2 - Spiro fused pyrrolidine-2,5-dione derivatives - Google Patents

Spiro fused pyrrolidine-2,5-dione derivatives

Info

Publication number
AU568709B2
AU568709B2 AU37199/84A AU3719984A AU568709B2 AU 568709 B2 AU568709 B2 AU 568709B2 AU 37199/84 A AU37199/84 A AU 37199/84A AU 3719984 A AU3719984 A AU 3719984A AU 568709 B2 AU568709 B2 AU 568709B2
Authority
AU
Australia
Prior art keywords
formula
hydrogen
group
atom
lower alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU37199/84A
Other languages
English (en)
Other versions
AU3719984A (en
Inventor
Shizuyoshi Fujimori
Yoshihiro Hirata
Tsutomu Irikura
Koichi Takagi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyorin Pharmaceutical Co Ltd
Original Assignee
Kyorin Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyorin Pharmaceutical Co Ltd filed Critical Kyorin Pharmaceutical Co Ltd
Publication of AU3719984A publication Critical patent/AU3719984A/en
Application granted granted Critical
Publication of AU568709B2 publication Critical patent/AU568709B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/08—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms with acylated ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyrrole Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AU37199/84A 1983-12-28 1984-12-28 Spiro fused pyrrolidine-2,5-dione derivatives Ceased AU568709B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP58245799A JPS60142984A (ja) 1983-12-28 1983-12-28 新規なスピロピロリジン−２，５−ジオン誘導体およびその製造法
JP58-245799 1983-12-28

Publications (2)

Publication Number Publication Date
AU3719984A AU3719984A (en) 1985-07-04
AU568709B2 true AU568709B2 (en) 1988-01-07

Family

ID=17139003

Family Applications (1)

Application Number Title Priority Date Filing Date
AU37199/84A Ceased AU568709B2 (en) 1983-12-28 1984-12-28 Spiro fused pyrrolidine-2,5-dione derivatives

Country Status (15)

Country Link
US (1) US4593092A (enExample)
EP (1) EP0147805B1 (enExample)
JP (1) JPS60142984A (enExample)
KR (1) KR900004589B1 (enExample)
AT (1) ATE57382T1 (enExample)
AU (1) AU568709B2 (enExample)
CA (1) CA1254559A (enExample)
DE (1) DE3483391D1 (enExample)
DK (1) DK615984A (enExample)
ES (2) ES8606353A1 (enExample)
HU (1) HU191740B (enExample)
MX (1) MX158152A (enExample)
PH (1) PH21187A (enExample)
PT (1) PT79759A (enExample)
ZA (1) ZA849931B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU596851B2 (en) * 1986-07-11 1990-05-17 Kyorin Pharmaceutical Co. Ltd. The process for the manufacture of spiro-linked pyrrolidine-2,5-diones

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6317886A (ja) * 1986-07-11 1988-01-25 Kyorin Pharmaceut Co Ltd スピロピロリジン−２，５−ジオン誘導体の製法
US5173489A (en) * 1986-04-10 1992-12-22 The Dupont Merck Pharmaceutical Co. α,α-disubstituted aromatics and heteroaromatics as cognition enhancers
US5300642A (en) * 1986-04-10 1994-04-05 The Du Pont Merck Pharmaceutical Company α, α-disubstituted aromatics and heteroaromatics as cognition enhancers
US5434264A (en) * 1988-08-23 1995-07-18 The Du Pont Merck Pharmaceutical Company α,α-disubstituted aromatics and heteroaromatics as cognition enhancers
US4946858A (en) * 1988-10-20 1990-08-07 American Home Products Corporation Novel spirosuccinimides as aldose reductase inhibitors and antihyperglycemic agents
US4900739A (en) * 1988-10-20 1990-02-13 American Home Products Corp. Novel spirosuccinimides as aldose reductase inhibitors and antihyperglycemic agents
TW202450B (enExample) * 1991-06-26 1993-03-21 Dainippon Pharmaceutical Co
US7510851B2 (en) * 2001-12-17 2009-03-31 Metabolex, Inc. Compositions and methods for diagnosing and treating diabetes, insulin resistance and dyslipidemia
AR053710A1 (es) 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
MY144968A (en) 2005-04-11 2011-11-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
EP2073806B1 (en) 2006-10-12 2012-02-15 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
BRPI0719166A2 (pt) * 2006-10-12 2014-06-03 Xenon Pharmaceuticals Inc Derivados de espiro-oxindol tricíclicos e seus usos como agentes terapêuticos
WO2010045197A1 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals, Inc. Spiro-oxindole compounds and their use as therapeutic agents
HRP20150882T1 (hr) 2008-10-17 2015-09-25 Xenon Pharmaceuticals Inc. Spirooksindolski spojevi i njihova upotreba kao terapijska sredstva
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
PE20170202A1 (es) 2009-10-14 2017-03-24 Xenon Pharmaceuticals Inc Metodos sinteticos para compuestos espiro-oxoindol
RU2596488C2 (ru) 2010-02-26 2016-09-10 Ксенон Фармасьютикалз Инк. Фармацевтические композиции спиро-оксиндольного соединения для местного введения и их применение в качестве терапевтических агентов
AR103636A1 (es) 2015-02-05 2017-05-24 Teva Pharmaceuticals Int Gmbh Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4193996A (en) * 1979-04-04 1980-03-18 Pfizer Inc. Spiro-quinolone hydantoins
IE53102B1 (en) * 1981-05-12 1988-06-22 Ici Plc Pharmaceutical spiro-succinimide derivatives
EP0065392B1 (en) * 1981-05-13 1985-02-13 Imperial Chemical Industries Plc Pharmaceutical compositions containing spiro succinimide derivatives

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU596851B2 (en) * 1986-07-11 1990-05-17 Kyorin Pharmaceutical Co. Ltd. The process for the manufacture of spiro-linked pyrrolidine-2,5-diones

Also Published As

Publication number Publication date
MX158152A (es) 1989-01-11
DE3483391D1 (de) 1990-11-15
EP0147805A2 (en) 1985-07-10
AU3719984A (en) 1985-07-04
DK615984A (da) 1985-06-29
JPH0370708B2 (enExample) 1991-11-08
EP0147805A3 (en) 1986-07-09
KR850004769A (ko) 1985-07-27
US4593092A (en) 1986-06-03
PT79759A (en) 1985-01-01
KR900004589B1 (ko) 1990-06-30
HU191740B (en) 1987-04-28
ES8702914A1 (es) 1987-01-16
DK615984D0 (da) 1984-12-20
EP0147805B1 (en) 1990-10-10
ZA849931B (en) 1985-08-28
ES8606353A1 (es) 1986-04-01
ES539208A0 (es) 1986-04-01
HUT37433A (en) 1985-12-28
ES549979A0 (es) 1987-01-16
JPS60142984A (ja) 1985-07-29
ATE57382T1 (de) 1990-10-15
CA1254559A (en) 1989-05-23
PH21187A (en) 1987-08-12

Similar Documents

Publication Publication Date Title
AU3719984A (en) Spiro fused pyrrolidine-2,5-dione derivatives
AU627832B2 (en) Imidazo(1,2-6)pyridazines, their production and use
DE3262294D1 (en) Pharmaceutical compositions containing spiro succinimide derivatives
HU9202105D0 (en) Tetrahydro-pyrrholo(1,2-a)pyrazine-4-spiro-3'-pyrrholidine derivatives method for producing them and pharmaceutical preparatives containing them
AU626740B2 (en) Aminocarbonylcarbamates related to physostigmine, a process for their preparation and their use as medicaments
GR3021971T3 (en) Imidazonaphthyridine derivatives
IE890464L (en) New 1,4-Benzoxazine and 1,4-Benzothiazine Derivatives and process for their preparation
NO894384L (no) Forbindelser for behandling av urininkontinens.
FI912499A0 (fi) Pyrido/3,4-b/pyrrolo/1,2-e//1,4,5/ oxadiazepiner och daermed naerbeslaektade analoger, foerfarande foer deras framstaellning och deras anvaendning som laekemedel.
AU7876281A (en) Synthesis of indolines